about
Refractory schizophrenia and atypical antipsychoticsA review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdoseMelperone in treatment-refractory schizophrenia: a case seriesA decision analysis of long-term lithium treatment and the risk of renal failurePsilocybin with psychological support for treatment-resistant depression: an open-label feasibility studyShould psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studiesLeukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study.Assessing QT interval prolongation and its associated risks with antipsychotics.Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy.Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization.Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients.Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis.Tolerability of atypical antipsychotics.Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009.Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management.Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS/MS.Psychiatric side effects of non-psychiatric drugs.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia.Factors associated with non evidence-based prescribing of antipsychoticsAntidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety.Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme.Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota.The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases.Factors predicting use of laxatives in outpatients stabilized on clozapine.A review of atypical antipsychotic drugs versus conventional medication in schizophrenia.Behavioral interventions for antipsychotic induced appetite changes.Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials.Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists.Predictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.Increased use of antipsychotic long-acting injections with community treatment orders.Clozapine-related EEG changes and seizures: dose and plasma-level relationships.Bipolar depression: clinically missed, pharmacologically mismanaged.Does clozapine cause or worsen obsessive compulsive symptoms? An analysis and literature review.
P50
Q22241831-163354B1-184A-4769-93C6-A6E7E87D2900Q24606269-F5F59E76-E381-406A-8A6D-389CFF2D5994Q24633079-97A6604A-1AB1-498E-BBED-3C2AB3FA03F2Q27004676-2019AB8F-B41D-471B-82DA-85478DDFB72FQ28005551-C4845087-EF55-4BD2-A45A-84DB870D6424Q28109603-8E20D7D0-978E-4E56-8902-8EBE2E0B3C39Q28236293-7A1403B8-DD85-4EE7-BED8-4D9CAC6F67DFQ30528442-6C6734BD-71D8-4E01-A381-63D734902E27Q33160123-9F00A0F8-B15D-497B-8D3C-2365E04DA60BQ33268080-9EA97E70-4BEE-467F-8F0E-44BCC7F7EA6AQ33718170-C290539A-03BB-4594-B48E-D5E179FF5838Q33785456-0E553285-D92D-43C4-A7A6-FD180927D220Q33844493-985EC9AE-A88F-4DEB-983F-66267E9F95DFQ33876248-422B8B67-A469-41F7-8EFB-05AD1209C394Q33939024-EE317E85-3622-4A12-88A4-F5B0FC082A13Q34072466-4C5B8BB5-7716-4556-AFAE-BF1EA893FA2CQ34119373-1721C7D4-F5C0-4B01-B184-604CDA7AF053Q34126160-C595D8FF-E261-451F-95A1-F203348B1D49Q34138808-9CC3829F-20B5-4EAA-82FE-A95FF607202FQ34418847-BE20EE72-B71D-4CCD-9FCD-59E34C96680EQ34441802-433408A0-61AF-4AE0-BB4D-6F3AE309DB4CQ34560981-12407852-BD36-4FFF-96B1-ED8A7A690CFAQ34642808-842209D1-2E48-4BD8-B3DD-F0C244440147Q34825537-437DD138-8E69-4E20-A48A-8BE26E13BC9DQ34869256-766D8000-A3F7-40CF-AA03-0AEDEC656D4FQ35044176-88B35F11-35EB-4844-8DBD-413B2759E35BQ35669153-8E7DCAEC-9BD9-440C-824D-C8842BAE9F1CQ35731977-664A23B6-2A9F-4D0F-9C16-D9126BA756D9Q36074323-0A7C55E3-005B-4349-8F4B-17DD158F6993Q36211684-9812B6F5-3CAB-44A6-8D27-6DCEA0B09788Q36573892-AF27F393-0017-434C-825F-CEB812E4C0A4Q36651040-6894F4D5-BC4C-4C87-B57F-5FE307B78A55Q36893286-B0CE69AE-1CD1-4C86-8BA4-905DD69A4C54Q36936379-D2EC42EA-91F1-4A00-8AA0-B4192EE27E68Q36946353-B29DFFA4-3596-4EF5-A70E-6E6C8630A4A9Q37042072-741FC188-19AE-4EC3-AB6A-750BECB3CE96Q37078942-BCBED879-49BE-4DEC-A337-F2B0FCBD34F4Q37078947-4E905A00-4C5E-4CB2-9A67-6321736D5B98Q37078950-01530266-50DF-4DEF-B02B-47B354D4DD7EQ37078970-E1FAB4E9-91CA-46B7-8D5B-0D298D04D490
P50
description
researcher ORCID: 0000-0002-2557-1710
@en
name
David Taylor
@ast
David Taylor
@en
David Taylor
@es
David Taylor
@nl
David Taylor
@sl
type
label
David Taylor
@ast
David Taylor
@en
David Taylor
@es
David Taylor
@nl
David Taylor
@sl
prefLabel
David Taylor
@ast
David Taylor
@en
David Taylor
@es
David Taylor
@nl
David Taylor
@sl
P214
P244
P106
P1153
55475229800
P21
P214
P244
n2017185137
P271
DA13586103
P31
P496
0000-0002-2557-1710
P734
P735
P7859
lccn-n2017185137